Once-daily radiotherapy to ≥59.4 Gy versus twice-daily radiotherapy to ≥45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes
- 138 Downloads
The aim of this study was to compare toxicities, disease control, survival outcomes, and patterns of failure between groups of limited-stage small-cell lung cancer patients treated with once-daily versus twice-daily radiotherapy and concurrent chemotherapy.
Materials and methods
This single-institution retrospective analysis included a comparison of two of radiotherapy regimens to planned doses of (1) ≥59.4 Gy at 1.8–2.0 Gy per once-daily fraction or (2) ≥45 Gy at 1.5 Gy per twice-daily fractions with concurrent platinum-based chemotherapy. Comparative analyses of toxicities and disease control were performed.
A total of 71 patients were included in the present study (17 once-daily, 54 twice-daily). Patient, tumor, staging, and treatment factors were similar between the two treatment groups. Median planned radiotherapy doses were 60 Gy (range 59.4–70.0 Gy) and 45 Gy (range 45–51 Gy) for the once-daily and twice-daily groups, respectively. Acute toxicities were similar between the groups (∼20% grade 3 esophagitis). At a median survival follow-up of 26.2 months (range 3.4–85.5 months), 42 patients had died. The 2-year overall survival estimates were similar at 43% and 49% for the once-daily versus twice-daily groups, respectively. Isolated in-field failures were similar between the two groups (∼17%).
The present analysis did not detect a statistically significant difference in acute toxicities, disease control, or survival outcomes in limited-stage small-cell lung cancer patients treated with concurrent chemotherapy and once-daily versus twice-daily radiotherapy.
Key wordsHyperfractionation Small-cell carcinoma Lung neoplasms Combined-modality therapy Radiotherapy
Unable to display preview. Download preview PDF.
- 5.Uno T, Sumi M, Ishihara Y, Numasaki H, Mitsumori M, Teshima T, et al. Changes in patterns of care for limited-stage small-cell lung cancer: results of the 99-01 patterns of care study: a nationwide survey in Japan. Int J Radiat Oncol Biol Phys 2008;27:414–419.Google Scholar
- 6.Komaki R, Swann RS, Ettinger DS, Glisson BS, Sandler AB, Movsas B, et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys 2005;62:342–350.PubMedGoogle Scholar
- 7.Choi NC, Herndon JE, Rosenman J, Carey RW, Chung CT, Bernard S, et al. Phase I study to determine the maximumtolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998;16:3528–3536.PubMedGoogle Scholar
- 8.Bradley JD, Graham M, Suzanne S, Byhardt R, Govindan R, Fowler J, et al. Phase I results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC. J Clin Oncol 2005;23(suppl 1):A7063.Google Scholar
- 9.Sause W, Kolesar P, Taylor S, Johnson D, Livingston R, Komaki R, et al. Final results of phase III trial regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358–364.CrossRefPubMedGoogle Scholar
- 10.Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Group Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005;23:5901–5907.CrossRefGoogle Scholar
- 14.Videtec GM, Belderbos JS, Kong FM, Kepna L, Martel MK, Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants’ meeting on elective nodal irradiation in lung cancer: small-cell lung cancer (SCLC). Int J Radiat Oncol Biol Phys 2008;72:327–334.Google Scholar
- 16.Watkins JM, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Fortney JA, et al. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009;74:1108–1113.PubMedGoogle Scholar